Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 16 Jun 2017 Planned End Date changed from 31 Jan 2018 to 1 Jan 2018.
- 16 Jun 2017 Planned primary completion date changed from 31 Jan 2018 to 1 Jan 2018.
- 16 Jun 2017 Status changed from recruiting to active, no longer recruiting.